Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
MDP Stock Chart & Stats
C$2.86
C$0.09(2.60%)
At close: 4:00 PM EST
C$2.86
C$0.09(2.60%)
Day’s Range― - ―
52-Week RangeC$1.96 - C$3.61
Previous CloseN/A
Volume43.25K
Average Volume (3M)46.68K
Market Cap
C$92.06M
Enterprise ValueC$77.91M
Total Cash (Recent Filing)C$14.97M
Total Debt (Recent Filing)C$25.35M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Jun 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding32,300,380
10 Day Avg. Volume30,861
30 Day Avg. Volume46,683
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.19
Price to Sales (P/S)0.32
P/FCF Ratio1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside109.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Earnings ConsistencyAnalyst notes reported results were broadly in line with estimates, supporting earnings predictability that could stabilize the stock.
Growth FoundationsAnalyst states good groundwork is being laid for future growth through strategic initiatives that could expand revenue potential.
Product RecoveryRasuvo is set to rebound, which could boost product revenues and improve overall sales momentum.
Bears Say
Channel Inventory HeadwindsGrafapex product revenues were lighter than expected because of channel inventory management, creating near-term revenue pressure.
Elevated Risk ProfileThe stock is classified as above-average risk, reflecting higher volatility and potential downside for risk-sensitive investors.
Usage Versus Reported RevenueGrafapex flat revenues mask underlying usage momentum, creating a disconnect that could delay visible sales improvement.
Medexus Pharmaceuticals Inc News
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.96 and its highest was C$3.61 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Medexus Pharmaceuticals Inc’s market cap is C$92.06M.
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jun 30, 2026 which is in 129 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 11, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.031 by C$0.031.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -0.02.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 32,300,380 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.031. Following the earnings report the stock price went down -2.491%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$6.00 (109.79% Upside)
C$6.00 (109.79% Upside)
Insider Transactions
Bought Shares
Worth C$94.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.84%
12-Months-Change
Fundamentals
Return on Equity
0.87%
Trailing 12-Months
Asset Growth
4.14%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
MDP Stock 12 Month Forecast
Average Price Target
C$6.00
▲(109.79% Upside)
Technical Analysis
Options Prices
Currently, No data available
---